Valion Bio
VBIO
7 hedge funds and large institutions have $119K invested in Valion Bio in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 7 → 7 (0)
7.83% less ownership
Funds ownership: 12.46% → 4.64% (-7.8%)
79% less capital invested
Capital invested by funds: $567K → $119K (-$448K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$43K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.4K |
| 3 |
Citigroup
New York
|
+$8.14K |
| 4 |
MG
Marex Group
London,
|
+$5.82K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$156K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MG
1
Marex Group
London,
| $59.4K | +$5.82K | +2,549 | +7% |
|
|
2
UBS Group
Zurich,
Switzerland
| $28.5K | +$43K | +18,858 | +2,354% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $21.2K | +$33.4K | +14,639 | New |
|
|
4
Citigroup
New York
| $7.25K | +$8.14K | +3,568 | +250% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.39K | +$3.76K | +1,648 | New |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $23 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $19 | +$11 | +5 | +63% |
|
|
DS
8
DRW Securities
Chicago,
Illinois
| – | -$156K | -53,935 | Closed |
|
VBIO Hedge Fund Activity: Q4 2025 in Review
7 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2025, worth a combined $119K — down 79% from $567K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VBIO positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $43K. The largest seller was DRW Securities, exiting entirely with an estimated $156K sold.
- 7 institutional investors held Valion Bio (VBIO) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $119K of Valion Bio stock for Q4 2025, down 79% quarter-over-quarter.
- 2 funds opened new Valion Bio positions in Q4 2025 and 1 closed out, a net change of +1 holder.
- The largest Valion Bio buyer in Q4 2025 was UBS Group, an estimated $43K added.
- The largest Valion Bio seller in Q4 2025 was DRW Securities, an estimated $156K sold.
Based on aggregated 13F filings for Q4 2025.